Synthesis and biological evaluation of 18F-FB-NGA as a hepatic asialoglycoprotein receptor PET imaging agent
NUCLEAR CHEMISTRY, RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE|Updated:2021-01-20
|
Synthesis and biological evaluation of 18F-FB-NGA as a hepatic asialoglycoprotein receptor PET imaging agent
Nuclear Science and TechniquesVol. 24, Issue 6, Article number: 060301(2013)
Affiliations:
1.Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine,Wuxi 214063, China
2.Department of Clinical Laboratory Science, the First Wuxi Affiliated Hospital of Nanjing Medical University, Wuxi Clinical Science Research Institute, Wuxi 214063, China
Xiaobo GU, Gangming CAI, Mengjun JIANG, et al. Synthesis and biological evaluation of 18F-FB-NGA as a hepatic asialoglycoprotein receptor PET imaging agent. [J]. Nuclear Science and Techniques 24(6):060301(2013)
DOI:
Xiaobo GU, Gangming CAI, Mengjun JIANG, et al. Synthesis and biological evaluation of 18F-FB-NGA as a hepatic asialoglycoprotein receptor PET imaging agent. [J]. Nuclear Science and Techniques 24(6):060301(2013) DOI: 10.13538/j.1001-8042/nst.2013.06.016.
Synthesis and biological evaluation of 18F-FB-NGA as a hepatic asialoglycoprotein receptor PET imaging agent
Asialoglycoprotein receptor (ASGP-R) is a hepatic membrane receptor that uniquely exists on the surface of mammalian hepatocytes, and has been used as target of liver functional imaging agents for many years. We labeled the Galactosyl-neoglycoalbumin (NGA) with,18,F to get a PET molecular probe ,18,F-FB-NGA and evaluated its ability as a liver functional PET imaging agent. The ,18,F-FB-NGA was prepared with NGA by conjugation with ,N,- succinimidyl-4-,18,F-fluorobenzoate (,18,F-SFB) and purified with PD-10 desalting column. The radiolabeling yield and radiochemical purity of ,18,F-FB-NGA were determined by radio-HPLC. Starting with ,18,F-F,–, the total time for ,18,F-FB -NGA was about 120±10 min. The decay-corrected radiochemical yield is about 25–30%. The radiochemical purity of purified ,18,F-FB-NGA was more than 98%. Labeled with 185–1850 MBq ,18,F-SFB, the specific activity of ,18,F -FB- NGA was estimated to be 7.83–78.3 TBq/mmol. Biodistribution of ,18,F-FB-NGA in normal mice was investigated after injection through the tail vein. The results showed that the liver accumulated 39.47±3.42 and 12.12±6.11%ID/g at 10 and 30 min after injection, respectively. Dynamic MicroPET images in mice were acquired with and without block after injection of the radiotracer, respectively. High liver activity accumulation was observed at 5 min after injection in normal group. On the contrary, the liver accumulation was significantly lower after block, indicating the specific binding to ASGP-R. ,18,F-FB-NGA is probably a potential PET liver imaging agent.
Preliminary evaluation of the radiotherapeutic efficacy of 131I-atorvastatin in rats with hepatocellular carcinoma
Preparation and biodistribution assessment of 68Ga-DKFZ-PSMA-617 for PET prostate cancer imaging
Semi-automated synthesis, validation and microPET imaging of 18F-FP-DTBZ as a vesicular monoamine transporter ligand
Directly radiolabeled phage with spleen-targeting specificity
Nanographene oxide labeling with 188Re
Related Author
No data
Related Institution
.O. BOX
Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences
Department of Chemistry, University of Zanjan
Nuclear Science and Technology Research Institute (NSTRI)
Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, College of Chemistry and Molecular Engineering, Peking University